Three-Year study tests if new hemophilia drug protects joints and boosts activity
NCT ID NCT05181618
Summary
This study is observing people with moderate to severe hemophilia A who are switching to a preventive drug called emicizumab. Researchers want to see how well this long-term treatment protects their joints from damage and helps them stay physically active over three years. The study involves 136 participants aged 13 to 70 who will be monitored using joint ultrasounds, activity trackers, and questionnaires.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AOU Careggi
Florence, Tuscany, 50134, Italy
-
AOU Federico II
Naples, Campania, 80131, Italy
-
Akdeniz Uni School of Medicine
Antalya, 07059, Turkey (Türkiye)
-
Aziza Othmana Hospital
Tunis, Tunisia
-
CHU Farhat Hached
Sousse, 4000, Tunisia
-
Charité Universitätsklinikum Berlin
Berlin, 13353, Germany
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
Ege Uni Medical School
Izmir, 35100, Turkey (Türkiye)
-
Gazi Universitesi Tip Fakultesi
Ankara, 06500, Turkey (Türkiye)
-
Hamilton Health Sciences Corporation
Hamilton, Ontario, L9H 2B7, Canada
-
Hospital Regional Universitario Carlos Haya
Málaga, 29010, Spain
-
Hospital Universitario Vall de Hebron
Barcelona, 08035, Spain
-
Hospital Universitario la Paz
Madrid, 28046, Spain
-
Hospital das Clinicas - UNICAMP
Campinas, São Paulo, 13083-878, Brazil
-
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
Ribeirão Preto, São Paulo, 14051-140, Brazil
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08025, Spain
-
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique
Rabat, 10090, Morocco
-
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, 20122, Italy
-
Istanbul University Cerrahpasa Medical Faculty
Istanbul, 34098, Turkey (Türkiye)
-
Manchester University NHS Foundation Trust (MFT)
Manchester, M13 9WL, United Kingdom
-
Oklahoma Children's Hospital ? Jimmy Everest Center
Oklahoma City, Oklahoma, 73104, United States
-
Orthopaedic Institute for Children
Los Angeles, California, 90007, United States
-
Policlinico Univ. A. Gemelli
Rome, Lazio, 00168, Italy
-
St Thomas Westminster
London, SE1 7EH, United Kingdom
-
University Clinical Centre of Serbia
Belgrade, 11000, Serbia
-
University of Miami Medical Center
Miami, Florida, 33136, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Észak-Pesti Centrumkórház - Honvédkórház
Budapest, 1134, Hungary
Conditions
Explore the condition pages connected to this study.